Muzaffar Qazilbash, MD, Professor at the University of Texas MD Anderson Cancer Center, Houston, TX, discusses considerations for treating young patients with multiple myeloma. Standard treatment includes induction treatment followed by autologous stem cell transplant and maintenance treatment. Dr Qazilbash discusses the benefits and risks of induction combinations, including an explanation for the choice of VRd (bortezomib, lenalidomide, dexamethasone) as the standard induction treatment. According to Dr Qazilbash, proteasome inhibitors such as bortezomib or carfilzomib, along with lenalidomide as maintenance treatment should be used for high-risk patients.